drugset / Trial / NCT00263887

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

NCT00263887 ↗

Phase 2 Completed 77 enrolled Grifols Therapeutics LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this trial was to explore the utility of evaluating emphysema progression through CT scans measuring lung density during a 2 year period of weekly infusions of either placebo or human alpha-1-antitrypsin (AAT; Prolastin®). Exacerbation data recorded in patient diaries were also collected. All efficacy data were analyzed for potential use in evaluating Prolastin efficacy in this and other clinical trials.

Timeline

Start
2003-12
Primary completion
2007-01
Completion
2007-01

Outcome

Met primary endpoint

registry analysis (superiority or other test); Prolastin (60 mg/kg Body Weight) vs Placebo; p = 0.049; ANCOVA NCT00263887 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alpha 1-Antitrypsin Protein / enzyme biologic 60 mg/kg Intravenous